Clik here to view.
AASLD 2015: 3-Drug Combos for 8 Weeks Demonstrate High Hepatitis C Cure Rate
An interferon-free regimen containing Merck's grazoprevir, the NS5A inhibitors elbasvir or MK8404, and the experimental nucleotide polymerase inhibitor MK-3682, taken for 8 weeks, cured more than 90%...
View ArticleClik here to view.
AbbVie Opens Global Phase 3 Studies of ABT-493/ABT-530 Hepatitis C Regimen
AbbVie has started enrollment of a projected 1600 participants in 6 new international Phase 3 clinical trials evaluating a once-daily regimen of its investigational NS3/4A protease inhibitor ABT-493...
View ArticleClik here to view.
FDA Approves Zepatier (Grazoprevir/Elbasvir) for Hepatitis C Genotypes 1 and 4
The U.S. Food and Drug Administration (FDA) this week announced its approval of Merck's Zepatier -- a once-daily coformulation containing the hepatitis C virus (HCV) protease inhibitor grazoprevir and...
View ArticleClik here to view.
AASLD 2015: MiR-122 Inhibitor RG-101 Suppresses Hepatitis C Virus with Single...
A single injection of RG-101, an experimental drug that targets the micro RNA miR-122 in liver cells, reduced hepatitis C virus (HCV) levels by more than 4 log in people with HCV genotypes 1, 3, and...
View ArticleClik here to view.
FDA Approves Daclatasvir + Sofosbuvir for Hard-to-Treat Hepatitis C Patients
The U.S. Food and Drug Administration (FDA) this month approved an expanded indication for Bristol-Myers Squibb's daclatasvir (Daklinza) and Gilead Sciences sofosbuvir (Sovaldi) for additional patient...
View ArticleClik here to view.
FDA Approves Harvoni for Hepatitis C Patients with Advanced Liver Disease
The U.S. Food and Drug Administration (FDA) has approved an expanded indication for Gilead Sciences sofosbuvir/ledipasvir coformulation (Harvoni) plus ribavirin for genotype 1 chronic hepatitis...
View ArticleClik here to view.
Daclatasvir Plus Asunaprevir Cures Most Genotype 1b Chinese Hepatitis C Patients
An interferon- and ribavirin-free dual combination of Bristol-Myers Squibb's hepatitis C virus (HCV) NS5A inhibitor daclatasvir (Daklinza) and HCV protease inhibitor asunaprevir (Sunvepra) produced...
View ArticleClik here to view.
Coverage of the 2016 Conference on Retroviruses and Opportunistic Infections
HIVandHepatitis.com coverage of the 2016 Conference on Retroviruses and Opportunistic infections (CROI 2016), February 22-25, 2016, in Boston. Conference highlights include PrEP and other HIV...
View ArticleClik here to view.
CROI 2016: Ravidasvir Plus Sofosbuvir Demonstrates High Cure Rate for HCV...
Sofosbuvir plus the investigational HCV NS5A inhibitor ravidasvir, with or without ribavirin, cured 95% to 100% of people with hepatitis C virus (HCV) genotype 4, the most common type in Egypt,...
View ArticleClik here to view.
EASL 2016: Novel Therapy RG-101 Plus Antivirals Could Cure Hepatitis C in 4...
Two injections of RG-101, an experimental drug that targets the micro RNA miR-122 in liver cells, combined with direct-acting antiviral agents (DAAs) taken for just 4 weeks led to 12-week...
View ArticleClik here to view.
Coverage of the 2016 EASL International Liver Congress
HIVandHepatitis.com coverage of the 2016 European Association for the Study of the Liver International Liver Congress (EASL 2016) in Barcelona, April 13-17, 2016. Conference highlights include...
View ArticleClik here to view.
EASL 2016: Adolescents with Hepatitis C Achieve High Cure Rates with...
Sofosbuvir/ledipasvir (Harvoni) was well-tolerated and led to sustained virological response in 97% of adolescents (age 12-17) with chronic hepatitis C, with high cure rates regardless of prior...
View ArticleClik here to view.
EASL 2016: Vaccines for HIV and Hepatitis C Could Potentially Be Administered...
Immunization against HIV and hepatitis C virus (HCV) could potentially be combined without compromising immune response to either, though effective vaccines for both diseases are still elusive,...
View ArticleClik here to view.
EASL 2016: DAAs for Hepatitis C Achieve Excellent Outcomes in Real-World...
Hepatitis C therapy with direct acting antivirals (DAAs) is as effective in real-world settings as it was in clinical trials, according to U.S. research presented at the International Liver Congress...
View ArticleClik here to view.
EASL 2016: AbbVie Pangenotypic Combination Achieves High Cure Rate for...
A new combination of direct-acting antivirals developed by AbbVie -- ABT493 and ABT-530 -- is highly effective in curing people with genotype 3 hepatitis C virus (HCV) infection and liver cirrhosis,...
View ArticleClik here to view.
EASL 2016: Portugal's Roll-Out of Hepatitis C DAA Therapy Achieves Impressive...
Roll-out of hepatitis C therapy using direct-acting antivirals (DAAs) has achieved excellent outcomes in Portugal, data presented to the International Liver Congress in Barcelona shows. Overall, 96%...
View ArticleClik here to view.
EASL 2016: ABT-493 + ABT-530 Works Well for Patients Who Did Not Respond to...
An experimental combination of direct acting antivirals (DAAs) from AbbVie is effective and safe in patients with hepatitis C virus (HCV) genotype 1 who did not respond to previous DAA therapy,...
View ArticleClik here to view.
EASL 2016: WHO Issues New Hepatitis C Guidelines, EASL Guidelines Update Coming
In April, coinciding with the International Liver Congress in Barcelona, the World Health Organization (WHO) released an update to its Guidelines for the Screening, Care and Treatment of Patients with...
View ArticleClik here to view.
DDW 2016: Sofosbuvir/ Velpatasvir Produces High Hepatitis C Cure Rates in...
A coformulation of Gilead Science's sofosbuvir and its investigational hepatitis C virus (HCV) NS5A inhibitor velpatasvir taken for 12 weeks produced sustained virological response in 95% to 99% of...
View ArticleClik here to view.
DDW 2016: ABT-493 + ABT-530 Cures Most Hepatitis C Patients in SURVEYOR Studies
A coformulation of AbbVie's experimental next-generation direct-acting antiviral agents ABT-493 and ABT-530 was well-tolerated and led to sustained virological response in 97% or more of patients with...
View Article